Key facts
- This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Apr 2023, 08:00.
Christopher Downs - 17 Apr 2023 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CNSP
- Reported as of
- 17 Apr 2023
- Net transaction value
- +$9,920
- SEC form
- 4
- Accepted by SEC
- 18 Apr 2023, 08:00:05 UTC
- Prior SEC filing
- 31 Mar 2023
- Next SEC filing
- 01 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Downs
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 18 Apr 2023.
Change
- Previous filing in this sequence was filed on 31 Mar 2023.
- Current net transaction value: +$9,920.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNSP
transaction
Common Stock
Purchase
- Transaction value
- $9,920
- Shares
- +3,100
- Change %
- +50%
- Price
- $3.20
- Shares after
- 9,251
- Date
- 17 Apr 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.